Published October 31, 2012 by PR Web
St. Louis, MO (PRWEB) October 31, 2012
Pharmaceutical product liability lawyers at Carey Danis & Lowe have announced that they are undertaking an investigation into Wellbutrin claims. Attorneys at Carey Danis & Lowe are asking that individuals and families contact the law firm if they feel their child, or the child of a loved one, was born with a congenital heart defect due to the use of Wellbutrin during pregnancy.
Wellbutrin is a drug manufactured by GlaxoSmithKline, and is used in to treat patients suffering from depression as well as seasonal affective disorder (SAD), attention deficit disorder (ADD), and attention deficit hyperactivity disorder (ADHD). The U.S. Food and Drug Administration (FDA) has classified Wellbutrin as a Pregnancy Category C drug.
Wellbutrin allegedly causes birth defects include oral defects, congenital heart defects, Craniosynostosis, Omphalocele, and Persistent Pulmonary Hypertension of the Newborn (PPHN).
In addition, lawyers at Carey, Danis and Lowe are taking cases related to the use the use of Topamax. Prescribed to patients suffering from epilepsy and migraine headaches, Topamax is a drug manufactured by Ortho-McNeil-Janssen Pharmaceuticals Inc. Allegedly, Topamax can cause congenital oral defects in unborn children. The FDA has categorization Topamax as a Pregnancy Category D drug. Potential oral birth defects caused by Topamax include the development of a cleft lip and cleft palette.
In past pharmaceutical product liability cases, attorneys at Carey Danis & Lowe have aided plaintiffs in winning cases against pharmaceutical giants like GlaxoSmithKline and Ortho-McNeil-Janssen Pharmaceuticals Inc.
If a newborn baby has suffered birth defects allegedly caused by exposure in the womb to either Wellbutrin or Topamax, contact an attorney at Carey Danis & Lowe at 800.721.2519, or submit a claims form about filing a Wellbutrin lawsuit or a Topamax lawsuit.References: Pharmaceutical litigation, Topamax, Wellbutrin